Exploiting protein phosphatase inhibitors based on cantharidin analogues for cancer drug discovery

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 8, 2013, Pages 1166-1176

  Deng, Liping ^a   Dong, Jian ^a   Wang, Wei ^b  

^a SHAOXING UNIVERSITY   (China)

^b Zhejiang Supor Pharmaceuticals   (China)

Author keywords

Antitumor; Cantharidin; Norcantharidin; PP1; PP2A; Structure activity relationship

Indexed keywords

ACID ANHYDRIDE; ALPHA FETOPROTEIN; BETA CYCLODEXTRIN; CANTHARIDIN; CANTHARIMIDE; LIPOSOME; NORCANTHARIDIN; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; COMPLEX FORMATION; CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; ENCAPSULATION; ENZYME INHIBITION; ESTERIFICATION; HUMAN; IC 50; KERATINOCYTE; NEOPLASM; NONHUMAN; STOMACH IRRITATION; STRUCTURE ACTIVITY RELATION; TUMOR VOLUME;

CANTHARIDIN; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; PROTEIN PHOSPHATASE 1; PROTEIN PHOSPHATASE 2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84881525886     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313080005     Document Type: Article

References (86)

1. Wang, G.S. Medical uses of mylabris in ancient China and recent studies. J. Ethnopharmacol., 1989, 26, 147-162.
2. McCluskey, A.; Ackland, S.P.; Gardiner, E.; Walkom, C.C.; Sakoff, J.A. The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design? Anticancer Drug. Des., 2001, 16, 291-303.
3. Fillmore, K.; Bagatell, K.; Dugan, B.S. Phospholipids and cantharidin induced acantholysis in human epidermis. J. Invest. Dermatol., 1966, 47, 606-607.
4. Yell, J.A.; Buge, S.M.; Dean, D. Cantharidin-induced acantholysis in Darier's disease: dose acantholysis initiate dyskeratosis. Br. J. Dermatol., 1994, 131, 40-47.
5. Peng, F.; Wei, Y. Q.; Tian, L.; Yang, L.; Zhao, X.; Lu, Y. Induction of apoptosis by norcantharidin in human colorectal carcin oma cell lines: involvement of the CD95 receptor/ligand. J. Can. Res. Clin. Oncol., 2002, 128, 223-230.
6. Chen, Y.J.; Kuo, C.D.; Tsai, Y.M; Yu, C.C.; Wang, G.S.; Liao, H.F. Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anti-Cancer Drugs, 2008, 19, 55-64.
7. Chen, Y.N.; Chen, J.C.; Yin, S.C.; Wang, G.S.; Tsauer, W.; Hsu, H.F.; Hsu, S.L. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int. J. Cancer, 2002, 100, 158-165.
8. Huh, J.E.; Kang, K.S.; Chae, C.; Kim, H.M.; Ahn, K.S.; Kim, S.H.; Roles of p38 and JNK mitogen-activated protein kinase pathways during cantharidin-induced apoptosis in U937 cells. Biochem. Pharmacol., 2004, 67, 1811-1818.
9. Wu, J.Z.; Situ, Z.Q.; Chen, J.Y.; Liu, B.; Wang, W. Chemosensitivity of salivary gland and oral cancer cell lines. Chin. Med. J., 1992, 105, 1026-1028.
10. Kok, S.H.; Chui, C.H.; Lam, W.S.; Chen, J.; Tang, J.C.; Lau, F.Y.; Cheng, G.Y.; Wong, R.S.; Chan, A.S. Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines. Int. J. Mol. Med., 2006, 17, 945-949.
11. Kok, S.H.; Chui, C.H.; Lam, W S.; Chen, J.; Tang, J.C.; Lau, F.Y.; Cheng, G.Y.; Wong, R.S.; Chan, A.S. Apoptogenic activity of a synthetic cantharimide in leukaemia: implication on its structural activity relationship. Int. J. Mol. Med., 2006, 18, 1217-1221.
12. Li, W.; Xie, L.; Chen, Z.; Zhu, Y.; Sun, Y.; Miao, Y.; Xu, Z.; Han, X. Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Science, 2010, 101, 1226-1233.
13. Millward, T.A.; Zolnierowicz, S.; Hemmings, B.A. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem. Sci., 1999, 24, 186-191.
14. Janssens, V.; Goris, J.; Van, H, C. PP2A: The expected tumor suppressor. Current Opinion in Genetics Development, 2005, 15, 34-41.
15. Williams, L.A.; Möller, W.; Merisor, E.; Kraus, W.; Rösner, H. In vitro antiproliferation/cytotoxic activity of cantharidin (Spanish Fly) and related derivatives. West Indian Med. J., 2003, 52, 10-13.
16. McCluskey, A.; Alistair, T. R. S.; Sakoff, J.A. Serine-Threonine Protein Phosphatase inhibitors: Development of Potential Therapeutic Strategies. J. Med. Chem., 2002, 45, 1151-1175.
17. Yoshiyasu, B.; Nozomu, H.; Mikiko, S. Optically active cantharidin analogues possessing selective inhibitory activity on Ser/Thr protein phosphatase 2B (calcineurin): implications for the binding mode. Bioorg. Med. Chem., 2005, 13, 5164-5170.
18. McCluskey, A.; Ackland, S.P.; Bowyer, M.C.; Baldwin, M.L.; Garner, J.; Walkom, C.C.; Sakoff, J.A. Cantharidin analogues: synthesis and evaluation of growth Inhibition in a panel of selected tumor cell lines. Bioorg. Chem., 2003, 31, 68-79.
19. Zeng, W.-N.; Lu, Y. Advance on the synthesis and activities of cantharidin and its derivatives. Chinese J. Org. Chem., 2006, 26, 579-591.
20. An, Z.; Wang, Z.; Zhao, Y. Progress in the anti-tumor studies of cantharidin and its derivatives. Asia-Pacific Traditional Med., 2009, 5, 128-130.
21. Kok, S.H.; Hong, C.Y.; Kuo, M.Y.; Lee, C.H.; Lee, J.J.; Lou, I.U.; Lee, M.S.; Hsiao, M.; Lin, S.K. Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncology, 2003, 39, 19-26.
22. Chang, C.; Wu, J.; Zhang, J.M.; Zhu, Y.Q. Norcantharidin (NCTD) induces mitochondria mediated apoptosis in human HepG2 cells. Afr. J. Biotechnol., 2011, 10, 5370-5376.
23. An, W.W.; Wanf, M.W.; Tashiro, S.I.; Onodera, S.; Ikejima, T. Mitogen-activated protein kinase-dependent apoptosis in norcantharidin-treated A375-S2 cells is proceeded by the activation of protein kinase C. Chin. Med. J., 2005, 118, 198-203.
24. Fan, Y.Z.; Fu, J.Y.; Zhao, Z.M.; Chen, C.Q. Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells. World J. Gastroenterol., 2005, 11, 2431-2437.
25. Fan, Y.Z.; Fu, J.Y.; Zhao, Z.M.; Chen, C.Q. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. Hepatobiliary & Pancreatic Diseases International, 2007, 6, 72-80.
26. Yang, H.; Guo, W.; Xu, B.; Li, M.; Cui, J. Anticancer activity and mechanisms of norcantharidin-Nd3II on hepatoma. Anticancer Drugs 2007, 18, 1133-1137.
27. Chen, Y.J.; Shieh, C.J.; Tsai, T.H.; Kuo, C.D.; Ho, L.T.; Liu, T.Y.; Liao, H.F. Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells. Anticancer Drugs, 2005, 16, 293-299.
28. An, W.W.; Gong, X.F.; Wang, M.W.; Tashiro, S.; Onodera, S.; Ikejima, T. Norcantharidin induces apoptosis in HeLa cells through caspase, MAPK, and mitochondrial pathways. Acta Pharmacol. Sin., 2004, 25, 1502-1508.
29. Liu, X.H.; Blazsek, I.; Comisso, M.; Legras, S.; Marion, S.; Quitter, P.; Anjo, A.; Wang, G.S.; Misset, J.L. Effects of Norcantharidin, a Protein Phosphatase Type-2A Inhibitor, on the Growth of Normal and Malignant Haemopoietic Cells. Eur. J. Cancer., 1995, 31, 953-963.
30. Deng, L.P.; Liu, F.M.; Wang, H.Y. 1,3-Dipolar cycloaddition reaction of novel 5,6-dehydronorcantharidin derivatives of substituted aromatic amines with potential antitumor activities. J. Heterocycl. Chem., 2005, 42, 13-l8.
31. Padmavathi, V.; Venugopal, R.K.; Padmaja, A.; Venugopalan, P. Unusual reaction of chloramine-T with araldoximes. Org. Chem., 2003, 68, 1567-1570.
32. Purevsurev.; Koblicova, Z.; Trojanek, J. Cantharidinimide, a novel substance from Mylabris mongolica dokht. Cesko-Slovenska. Pharma., 1987, 36, 32-34.
33. Lee, J.Y.; Chung, Y.J.; Bae, Y.S.; Ryu, S.H.; Kim, B.H. Synthesis of hexapeptide and tetrapeptide analogs of the immunomodulating peptides. J. Chem. Soc. Perkin. Trans., 1998, 2, 359-366.
34. Tomita, K.; Sugai, S.; Kobayashi, T.; Murakami, T. Studies on isoxazoles.VIII. Versatile syntheses and chemical properties of 3- chloroisoxazolium chlorides. Chem. Pharm. Bull., 1979, 27, 2398-2404.
35. Berson, J.A.; Reynolds, R.D.; Jones, W.M. The stereochemistry and mechanism of the Diels-Alder reaction. An"intenal"mechanism for the interconversion of endo-exo isomers. J. Amer. Chem. Soc., 1956, 78, 6094-6097.
36. Xue, J.J. The mechanism and clinical application prospect of norcantharidin. J. Prac. Med., 2007, 23, 138-139.
37. Sun, Z.X.; Zhao, T.D.; Wei, Y.L. Research in norcantharidininduced human liver tumor cell BEL-7402 apoptosis. Acta Anatom. Sin., 1999, 30(1), 65-68.
38. Zhao, J.S.; Chen, X. The influence of norcantharidin to growth of two tumor cells in vitro. Liaoning J. Traditional Chinese Med, 2004, 31(2), 157-158.
39. Liu, X.L.; Chen, J.X.; Liu, Y. Research in norcantharidin-induced HL-60 cell apoptosis. J. Beijing Univ. Tradit. Chin. Med., 2000, 23(4), 35-37.
40. Tang, L.Y.; Wang, Z.M.; Zheng, Q.Y. The inhibition of norcantharidin to ovarian cancer 3AO and AO cells in vitro. Acad. J. Second. Mil. Med. Univ., 1999, 20(2), 97-99.
41. Fan, Y.Z.; Fu, J.Y.; Zhao, Z.M. Influence of norcantharidin to proliferation and apoptosis of human primary gallbladder carcinoma cell line GBC-SD cell. Shanghai Med. J. 2003, 26, 1-4.
42. Fan, Y.Z.; Fu, J.Y.; Zhao, Z.M. Intervention effect of norcantharidin to human primary gallbladder carcinoma cell line GBC-SD cell and associated genes. Chin. J. Exp. Surgery, 2004, 21(5), 554-556.
43. Huang, S.; Pettaway, C.A.; Uehara, H.; Bucana, C.D.; Fidler, I.J. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene, 2001, 2(31), 4188-4197.
44. Lin, A.; Karin, M. NF-kappaB in cancer, a market target. Semin. Cancer. Biol., 2003, 13(2), 107-114.
45. Sun, Z.X.; Li, J.S. Antitumor research hot spot of norcantharidin. Northwest. Pharm. J., 1998, 13(5), 227-228.
46. Youns, M.; Hoheisel, J. D; Efferth, T. Traditional Chinese Medicines (TCMs) for Molecular Targeted Therapies of Tumors. Current Drug Discovery Technologies, 2010, 7, 37-45.
47. Kok, S.H.; Cheng, S.J.; Hong, C.Y.; Lee, J.J.; Lin, S.K.; Kuo, Y.S.; Chiang, C.P.; Kuo, M.Y.P. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Can. Lett., 2005, 217, 43-52.
48. Adam McCluskey, A.; Mirella A.; Keane, Cecilia C.; Walkom, Michael C.; Bowyer, Alistair T. R.; Sim, David J.; Young and Jennette A. Sakoffe. The First Two Cantharidin Analogues Displaying PP1 Selectivity. Bioorg. Med. Chem. Lett. 2002, 12, 391-393.
49. Zhang, T.S.; Chen, P.; Feng, J.T. Advances in norcantharidin-induced tumor cells apoptosis. Chin. J. Hosp. Pharm., 2006, 26, 468-470.
50. Liao, H.F.; Su, S.L.; Chen, Y.J.; Chou, C.H.; Kuo, C.D. Norcantharidin preferentially induces apoptosis in human leukemic Jurkat cells without affecting viability of normal blood mononuclear cells. Food and Chemical Toxicology, 2007, 45, 1678-1687.
51. Liao, H.F.; Su, S.L.; Chen, Y.J.; Chou, C.H.; Kuo, C.D. Norcantharidin induces cell cycle arrest and inhibits progression of human leukemic Jurkat T cells through mitogen-activated protein kinase-mediated regulation of interleukin-2 production. Toxicology in Vitro., 2011, 25, 206-212.
52. Zheng, L.H.; Bao, Y.L.; Wu, Y.; Yu, C.L.; Meng, X.Y.; Li, Y.X. Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. Cancer Lett., 2008, 272, 102-109.
53. Yang, E.B.; Tang, W.Y.; Zhang, K.; Cheng, L.Y.; Mack, P.O.P. Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett., 1997, 117, 93-98.
54. Zheng, Y.L.; Shi, C.L.; He, Y.X. Clinical research of norcantharidin treating hepatoma. Hebei Medicine, 2005, 11, 820-821.
55. Wong, E.; Giandomenico, C.M. Current status of platinum-based antitumor drug. Chem. Rev., 1999, 99, 2451-2466.
56. To, K.K.; Ho, Y.P.; Au-Yeung, S.C. Synergistic interaction between platinum- based antitumor agents and demethylcantharidin. Cancer Lett., 2005, 223, 227-237.
57. To, K.K.; Ho, Y.P.; Au-Yeung, S.C.; Wang X.N.; Lin, G.; Han, X.W. Potential New Antitumor Agents from an Innovative Combination of Demethylcantharidin, a Modified Traditional Chinese Medicine, with a Platinum Moiety. J. Med. Chem., 2001, 44, 2065-2068.
58. Bungo, M.; Fujiwara, Y.; Kasahara, K.; Nakagawa, K.; Ohe, Y.; Sasaki, Y.; Irino, S.; Saijo, N. Decreased Accumulation as a Mechanism of Resistance to Cis-diammin-edichloroplatinum (II) in Human Nonsmall Cell Lung Cancer Cell Lines: Relation to DNA Damage and Repair. Cancer. Res., 1990, 50, 2549-2553.
59. Eastman, A.; Schulte, N. Enhanced DNA Repair as a Mechanism of Resistance to Cis-diamminedichloroplatinum (II). Biochemistry, 1988, 27, 4730-4734.
60. Meijer, C.; Mulder, N. H.; Hospers, G. A. P.; Uges, D. R. A.; de Vries, E. G. E. The Role of Glutathione in Resistance to Cisplatin in a Human Small Cell Lung Cancer Cell Line. Br. J. Cancer., 1990, 62, 72-77.
61. McCluskey, A.; Walkom, C.; Bowyer, M.C.; Ackland, S.P.; Gardiner, E.; Sakoff, J.A. Cantharimides: A New Class of Modified Cantharidin Analogues Inhibiting Protein Phosphatases 1 and 2A. Bioorg. Med. Chem. Lett., 2001, 11, 2941-2946.
62. Kok, S.H.; Chui, C.H.; Lam, W.S.; Chen, J.; Lau, F.Y.; Wong, S.M.; Cheng, Y.M.; Lai, B.S.; Leung, W.T.; Yu, W.Y.; Tang, C.O.; Chan, S.C. Synthesis and structure evaluation of a novel cantharimide and its cytotoxicity on SK-Hep-1 hepatoma cells. Bioorg. Med. Chem. Lett., 2007, 17, 1155-1159.
63. Hill, T.A.; Stewart, S.G.; Auckland, S.P.; Gilbert, J.; Sauer, B.;. Sakoff, J.A.; McCluskey, A. Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation. Bioorg. Med. Chem., 2007, 17, 6126-6134.
64. Bajsa, J.; McCluskey, A.; Gordon, C.P.; Stewart, S.G.; Hill, T.A.; Sahu, R.;. Duke, S.O.; Tekwani, B.L. The antiplasmodial activity of norcantharidin analogs. Bioorg. Med. Chem. Lett., 2010, 20, 6688-6695.
65. McCluskey, A.; Ackland, S.P.; Bowyer, M.C.; Baldwin, M.L.; Garner, J.; Walkom, C.C.; Sakoff, J.A. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumor cell lines. Bioorg. Chem., 2003, 31, 68-79.
66. McCluskey, A.; Sakoff, J.A. Small molecule inhibitors of serine/ threonine protein phosphatases. Mini-Rev. Med. Chem., 2001, 1, 43-55.
67. Sakoff, J.A.; McCluskey, A. Protein phosphatase inhibition: structure based design. Towards new therapeutic agents. Curr. Pharm. Des., 2004, 10, 1139-1159.
68. McCluskey, A.; Keane, M.A.; Walkom, C.; Bowyer, M. C.; Sim, A. T. R.; Young, D.J.; Sakoff, J.A. The First Two Cantharidin Analogues Displaying PP1 Selectivity. Med. Chem. Lett., 2002, 12, 391-393.
69. Tatlock, J. H.; Linton, M.A.; Hou, X.J.; Kissinger, C.R.; Pelletier, L.A.; Showalter, R.E.; Tempczyk, A.; Villafranca, J.E. Structurebased design of novel calcineurin (PP2B) inhibitors. Bioorg. Med. Chem. Lett., 1997, 7, 1007-1012.
70. Enz, A.; Zenke, G.; Pombo-Villar, E. Protein phosphatase 2A catalytic subunit zeta /Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform/ Serine/threonine protein phosphatase 2A, catalytic subunit, beta isoform. Bioorg. Med. Chem. Lett., 1997, 7, 2513-2518.
71. Hart, M.E.; Chamberlin, A.R.; Walkom, C.; Sakoffand, J.A.; McCluskey, A. Modified norcantharidins: synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity. Bioorg. Med. Chem. Lett., 2004, 14, 1969-1973.
72. Stewart, S.G.; Hill, T.A.; Gilbert, J.; Ackland, S.P.; Sakoffand, J.A.; McCluskey, A. Synthesis and biological evaluation of norcantharidin analogues: Towards PP1 selectivity. Bioorg. Med. Chem., 2007, 15, 7301-7310.
73. Hill, T.A.; Stewart, S.G.; Benjamin, S.; Ackland, S.P.; Gilbert, J.; Sauer, B.;. Sakoff, J.A.; McCluskey, A. Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity. Bioorg. Med. Chem. Lett., 2007, 17, 3392-3397.
74. McCluskey, A. Bowyer, M.C.; Collins, E.; Sim, A.T.R.; Sako, J.A.; Baldwin, M.L. Anhydride Modified Cantharidin Analogues: Synthesis, Inhibition of Protein Phosphatases 1 and 2A and Anticancer Activity. Bioorg. Med. Chem. Lett., 2000, 10, 1687-1690.
75. Yeh, C.B.; Su, C.J.; Hwang, J.M.; Chou, M.C. Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells. Eur. J. Med. Chem., 2010, 45, 3981-3985.
76. Thaqi, A.; Scott, J.L.; Gilbert, J.; Sakoff, J.A.; McCluskey, A. Synthesis and biological activity of D-5,6-norcantharimides: importance of the 5,6-bridge. Eur. J. Med. Chem., 2010, 45, 1717-1723.
77. Filler, R.; Kobayashi, Y.; Yagupolskii, K.M. Organofluorine compounds in medicinal chemistry and biomedical applications. Elsevier Science Publishers B.V., Amsterdam, Netherlands, 1993; pp. 1-22.
78. Essers, M.; Wibbeling, B.; Haufe, G. Synthesis of the first fluorinated cantharidin analogues. Tetrahedron Lett. 2001, 42, 5429-5433.
79. McCluskey, A.; Taylor, C.; Quinn, R.J. Inhibition of protein phosphatase 2A by cantharidin analogues. Bioorg. Med. Chem. Lett., 1996, 6, 1025-1028.
80. Zhu, C.Y.; An, L.N. The preparation method of Cantharidin and its extract combining with β-cyclodextrin. C.N. Patent 101, 670, 113A, Mar. 17, 2010.
81. Chang, C.C.; Liu, D.Z.; Lin, S.Y.; Liang, H.J.; Hou, W.C.; Huang, W.J.; Chang, C.H.; Ho, F.M.; Liang, Y.C. Liposome encapsulation reduces cantharidin toxicity. Food Chem. Toxicol. 2008, 46, 3116-3121.
82. Tang, Y.M.; Zhang, J.Y. The preparation and application of CD19 monoclonal antibody immune liposomes. C.N. Patent 101, 112, 126A, Dec. 30, 2009.
83. Efferth, T. Microarray-based prediction of cytotoxicity of tumor cells to cantharidin. Oncology Reports 2005, 13, 459-63.
84. Efferth, T.; Rauh, R; Kahl, S.; Tomicic, M; Böchzelt, H.; Tome, M.E.; Briehl, M.M.; Bauer, R; Kaina, B. Molecular modes of action of cantharidin in tumor cells. Biochem. Pharmacol. 2005, 69, 811-818.
85. Rauh, R.; Kahl, S.; Boechzelt, H.; Bauer, R.; Kaina, B.; Efferth, T. Molecular biology of cantharidin in cancer cells. Chin. Med. 2007, 2, 8.
86. Romero, M.R.; Serrano, M.A.; Efferth, T.; Alvarez, M.; Marin, J.J.G. Effect of cantharidin, cephalotaxine and homoharringtonine on "in vitro" models of hepatitis B virus (HBV) and bovine viral diarrhoea virus (BVDV) replication. Planta Medica 2007, 73, 552-558.